Universal access to GLP-1 receptor agonists for eligible populations could reduce global obesity prevalence by half and save ...

Mounjaro was launched in India earlier this year, while many leading multinational pharma companies are in the race to ...

The global surge in diabetes cases is a key factor propelling the artificial pancreas device market, as a larger patient base fuels the need for effective diabetes management tools. Growing awareness ...

Two medications used to treat type-2 diabetes and chronic weight management have been found to produce a smaller weight-loss ...

Peptidomic comparison of islets from DIO mice and to lean controls. Body weights (a) and fasting blood glucose levels (b) of DIO mice vs lean controls. ... Methods The presence of insulin, glucagon, ...

Objective: Given the interest in glucagon antagonism as a potential treatment of diabetes, we tested the hypothesis that glucagon, in concert with insulin, supports the postabsorptive plasma ...

Twelve‐month treatment with glucagon like peptide‐1 receptor agonists, sodium‐glucose cotransporter‐2 inhibitors, and their combination were associated with a significant reduction of neurohumoral ...

Aberrant glucagon responses promoting hyperglycemia may be due to the impaired regulation of glucagon and insulin secretion, as well as disrupted alpha cell responses to insulin. 1,2.

And while glucose-responsive insulin delivery systems are in widespread clinical use to treat insulin insufficiency, the on-demand supplementation of glucagon for acute hypoglycemia treatment isn ...

A small study found that using mini-dose glucagon, with or without reducing basal insulin delivery rate, can help reduce exercise-induced hypoglycemia in adults with type 1 diabetes. Although the ...

The White House said Eli Lilly’s move to cap out-of-pocket costs for insulin at $35 for patients shows why Republicans should stop trying to repeal the Inflation Reduction Act.